Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1981 Jun;40(3):245–249. doi: 10.1136/ard.40.3.245

Acute adverse reactions attributed to allopurinol in hospitalised patients.

G T McInnes, D H Lawson, H Jick
PMCID: PMC1000756  PMID: 7247470

Abstract

Of 29 524 hospitalised medical patients monitored in a drug surveillance programme 1835 (6.2%) received the xanthine oxidase inhibitor allopurinol. After the exclusion of skin reactions adverse effects were attributed to this drug in 33 (1.8%) patients, the most frequent being haematological abnormalities (11 patients, 0.6%) and diarrhoea and drug fever (5 each, 0.3%). Adverse effects were dose-related. Reactions were unrelated to age, weight, reason for therapy, admission blood urea, or albumin concentrations. Acute exacerbation of gout was troublesome in 3 patients (1 in 600 exposed).

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arndt K. A., Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 1976 Mar 1;235(9):918–923. [PubMed] [Google Scholar]
  2. Coffey J. J., White C. A., Lesk A. B., Rogers W. I., Serpick A. A. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res. 1972 Jun;32(6):1283–1289. [PubMed] [Google Scholar]
  3. Elion G. B., Kovensky A., Hitchings G. H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966 Jul;15(7):863–880. doi: 10.1016/0006-2952(66)90163-8. [DOI] [PubMed] [Google Scholar]
  4. Elion G. B., Yü T. F., Gutman A. B., Hitchings G. H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968 Jul;45(1):69–77. doi: 10.1016/0002-9343(68)90008-9. [DOI] [PubMed] [Google Scholar]
  5. Grahame R., Scott J. T. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970 Sep;29(5):461–468. doi: 10.1136/ard.29.5.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jarzobski J., Ferry J., Wombolt D., Fitch D. M., Egan J. D. Vasculitis with allopurinol therapy. Am Heart J. 1970 Jan;79(1):116–121. doi: 10.1016/0002-8703(70)90401-1. [DOI] [PubMed] [Google Scholar]
  7. Jick H., Miettinen O. S., Shapiro S., Lewis G. P., Siskind V., Slone D. Comprehensive drug surveillance. JAMA. 1970 Aug 31;213(9):1455–1460. [PubMed] [Google Scholar]
  8. Kantor G. L. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA. 1970 Apr 20;212(3):478–479. [PubMed] [Google Scholar]
  9. McKendrick M. W., Geddes A. M. Allopurinol hypersensitivity. Br Med J. 1979 Apr 14;1(6169):988–988. doi: 10.1136/bmj.1.6169.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Medline A., Cohen L. B., Tobe B. A., Sellers E. M. Liver granulomas and allopurinol. Br Med J. 1978 May 20;1(6123):1320–1321. doi: 10.1136/bmj.1.6123.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mills R. M., Jr Severe hypersensitivity reactions associated with allopurinol. JAMA. 1971 May 3;216(5):799–802. [PubMed] [Google Scholar]
  12. Muggia F. M., Ball T. J., Jr, Ultmann J. E. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967 Jul;120(1):12–18. [PubMed] [Google Scholar]
  13. Rawlins M. D., Smith S. E. Influence of allopurinol on drug metabolism in man. Br J Pharmacol. 1973 Aug;48(4):693–698. doi: 10.1111/j.1476-5381.1973.tb08258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rundles R. W., Metz E. N., Silberman H. R. Allopurinol in the treatment of gout. Ann Intern Med. 1966 Feb;64(2):229–258. doi: 10.7326/0003-4819-64-2-229. [DOI] [PubMed] [Google Scholar]
  15. Simkin P. A. Management of gout. Ann Intern Med. 1979 May;90(5):812–816. doi: 10.7326/0003-4819-90-5-812. [DOI] [PubMed] [Google Scholar]
  16. Swank L. A., Chejfec G., Nemchausky B. A. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med. 1978 Jun;138(6):997–998. [PubMed] [Google Scholar]
  17. Vesell E. S., Passananti G. T., Greene F. E. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med. 1970 Dec 31;283(27):1484–1488. doi: 10.1056/NEJM197012312832703. [DOI] [PubMed] [Google Scholar]
  18. YUE T. F., GUTMAN A. B. EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. Am J Med. 1964 Dec;37:885–898. doi: 10.1016/0002-9343(64)90131-7. [DOI] [PubMed] [Google Scholar]
  19. Young J. L., Jr, Boswell R. B., Nies A. S. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974 Sep;134(3):553–558. doi: 10.1001/archinte.134.3.553. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES